We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > TD-0903

News List

Theravance Biopharma doses first patient in phase 2 Covid-19 trial with JAKi inhibitor TD-0903 pharmaceutical-business-review
June 30, 2020
Theravance Biopharma has dosed the first patient in the phase 2 study of lung-selective and nebulized Janus kinase inhibitor (JAKi) TD-0903 to treat hospitalised patients with acute lung injury (ALI) due to Covid-19.
First Subject Dosed in TD-0903 Study for Acute Lung Injury from COVID-19 americanpharmaceuticalreview
April 24, 2020
Theravance Biopharma announced the first healthy volunteer has been dosed in a Phase 1 study of TD-0903.
Theravance Initiates Study in ALI caused by COVID-19 contractpharma
April 24, 2020
TD-0903 has potential to inhibit cytokine storm associated with ALI and prevent progression to Acute Respiratory Distress Syndrome.
Theravance Responds to COVID-19 Pandemic contractpharma
April 14, 2020
Theravance Biopharma said that it is advancing TD-0903, a lung-selective nebulized Janus kinase inhibitor (JAKi) into clinical development.